Eli Lilly and Company (LLY) — closed signal from April 19, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 18, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$915.00 – $940.00Entry zone — fair-value band
$927.03Published — price the day we called it
$1,066.08Target — the price the thesis aimed for
$1,249.45Peak — highest point inside the window, not a realized return
$1,179.11Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 33 days.
Peak price
$1,249.45
peak on July 7, 2026 — not a realized returnPeak gain
+34.8%
peak, from the publication priceWindow close
$1,179.11
end-of-window price, context onlyDays to target
33
Window
April 19, 2026 – July 18, 2026
The thesis — published April 19, 2026
Predicted growth
+15%
over the measurement windowTarget price
$1,066.08
the price the thesis aimed forEntry zone
$915.00 – $940.00
the fair-value band we waited forPrice at publication
$927.03
published April 19, 2026Confidence
83%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Lilly's growth is coming mainly from strong demand for its medicines and solid execution, not just market excitement. A regulatory request about the obesity drug raises real risk, but a related trial update helped calm safety concerns. Shares are holding near the short-term trend, which suggests a reasonable 0-3 month setup rather than a runaway move.
Primary drivers
- Strong demand from GLP-1 and other drug businesses
- Trial update reinforced the safety and effectiveness story
- FDA data request is a clear but manageable headline risk
- Shares are holding near short-term trend support
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.